Skip to content
Markets News
Stocks1 min read

Summit jumps as FICO falls on mortgage scoring changes

Makkler Newsroom
September 29, 2026

Summit gained after AstraZeneca agreed to invest $2 billion, while CarMax beat earnings forecasts and FICO faced a new scoring framework.

Summit Therapeutics rose 17.1% in premarket trading Tuesday after AstraZeneca agreed to make a $2 billion strategic equity investment. Fair Isaac, known as FICO, fell 15% after a federal housing agency announced mortgage-pricing changes that could introduce competition to its credit-scoring business.

CarMax gained 3.7% after reporting fiscal second-quarter revenue and earnings above Wall Street expectations. The used-car retailer posted earnings of $1.16 per share, compared with analyst expectations of 68 cents, and revenue of $7.88 billion, versus forecasts of about $7.06 billion.

AstraZeneca’s investment will support a collaboration pairing Summit’s ivonescimab antibody with AstraZeneca’s oncology pipeline. AstraZeneca will acquire convertible preferred shares at a price equivalent to $18.36 per common share, a 10% premium to Summit’s five-day volume-weighted average price.

The Federal Housing Finance Agency said Fannie Mae and Freddie Mac will combine their separate mortgage-pricing matrices into one grid. The framework will include VantageScore alongside the traditional FICO Classic score, raising concerns about demand for FICO’s scoring products.

CarMax’s total net revenue increased 19.5%, while combined retail and wholesale unit sales rose 14.7% to 387,735. Comparable-store used-unit sales increased 13%.

U.S. stock futures hovered near unchanged early Tuesday after rising bond yields weighed on Wall Street in the prior session. Investors were looking ahead to new economic data.

Further reading

This article was produced with the help of AI technology. Based on reporting by the outlets listed above.

Comments (0)

Log in to join the discussion.Log in

No comments yet - be the first to weigh in.